Introduction {#s1}
============

Gliomas are the most common type of primary brain tumor ([@B1]) representing 75% of all malignant primary central-nervous-system (CNS) tumors in adults ([@B2]). In the updated 2016 version of the World Health Organization (WHO) classification of CNS tumors, gliomas are divided into circumscribed gliomas (WHO grade I) and diffusely-infiltrating gliomas (whether astrocytic or oligodendroglial, WHO grades II--IV) ([@B3]). Compared to circumscribed gliomas, diffusely-infiltrating gliomas exhibit a more relentless malignant progression, a reduced efficacy to various therapeutic approaches, and a higher risk of recurrence ([@B4]). Despite efforts to promote various new therapies and advances in the research of tumor biology, the prognosis for patients with gliomas, especially diffusely-infiltrating gliomas, is still bleak ([@B2], [@B5]). This is mainly due to a lack of accurate biomarkers and a poor understanding of the pathogenesis of gliomas, which leads to delayed diagnoses and ineffective therapeutic outcomes. Therefore, there is an urgent need to better understand the mechanisms underlying glioma and to find potential biomarkers and accurate therapeutic targets.

Long non-coding RNAs (lncRNAs) account for a major class of non-coding RNAs (ncRNAs) and measure a length \>200 nucleotides ([@B6], [@B7]). Recent studies have demonstrated that lncRNAs may be involved in gene expression via four different processes: epigenetic regulation, translational regulation, transcriptional regulation, and post-transcriptional regulation ([@B8]--[@B12]). Increasing evidence has suggested that lncRNAs are vital epigenetic regulators of mRNA expression and constitute an important fraction of the human transcriptome. Furthermore, there is a growing number of studies that have reported that lncRNAs play important roles in tumor genesis, progression, and metastasis, as well as many other cellular processes ([@B13]--[@B16]). Aberrant expression of lncRNAs may contribute to glioma pathogenesis, including cellular proliferation, apoptosis, and metastasis ([@B17]--[@B20]). The dysregulation of lncRNAs may serve as diagnostic biomarkers of early stages of glioma and could be exploited as therapeutic targets ([@B21]--[@B23]). However, the potential pathological and biological roles of lncRNAs and mRNAs in different degrees of glioma malignancy have yet to be elucidated.

Recently, the deep sequencing of transcriptomes is being utilized with a higher sensitivity for the identification of differential expression. Advances in next-generation, deep-sequencing technology have identified a number of ncRNAs. Here, we performed high-throughput transcriptome sequencing of glioma tissues and normal tissues to determine lncRNA and mRNA profiles, to investigate novel tumor-related lncRNAs and mRNAs in glioma, and to generate model profiles for future studies. We constructed a gene co-expression network for the differentially expressed lncRNAs and mRNAs in glioma tissues to further investigate the relationship between lncRNAs and mRNAs. We also conducted gene-ontology (GO) enrichment analysis and pathway-enrichment analysis for the differentially expressed lncRNAs and mRNAs. In addition, the five most differentially expressed lncRNAs and mRNAs were verified by quantitative real-time PCR (qRT-PCR).

Materials and Methods {#s2}
=====================

Patients and Samples
--------------------

We recruited 50 patients diagnosed with glioma or epilepsy and collected their tumor or normal tissues from March 2014 to December 2018. All the tumor patients were explicitly diagnosed with glioma by histopathological examination after surgery and were classified as grade II, grade III, and grade IV according to the CNS tumor-classification criteria (fourth edition) published by the WHO in 2016. Six normal tissues and 16 glioma tissues (grade II, six cases; grade III, four cases; and grade IV, six cases) were selected at random for high-throughput transcriptome sequencing, and qRT-PCR analysis was performed in the other samples. All the patients had no prior chemotherapy or radiotherapy and did not have any other serious diseases. The brain tissues for RNA-sequencing were transferred to −80°C storage within 60 min of resection. This experiment was approved by the Ethics committee of Nantong University, and all patients provided informed consent.

RNA Library Construction and RNA Sequencing
-------------------------------------------

Total RNA was extracted from the brain tissue samples using Trizol reagent (Invitrogen, Cat no.15596-026, USA), following the manufacturer\'s protocol. Ribosomal RNA was removed from the total RNA samples using Ribo-Zero rRNA Removal Kits (Illumina, USA), as per the manufacturer\'s instructions. RNA libraries were constructed using rRNA-depleted RNAs with TruSeq Stranded Total RNA Library Prep Kit (Illumina, USA), according to the manufacturer\'s instructions. The libraries were controlled for quality and quantified using the BioAnalyzer 2,100 system (Agilent Technologies, USA). Then, the 10-pM libraries were denatured as single-stranded DNA molecules, captured on Illumina flow cells, amplified *in situ* as clusters, and finally amplified (150 cycles) and sequenced on an Illumina HiSeq Sequencer, according to the manufacturer\'s instructions.

The high-quality reads generated were aligned to the human reference genome (UCSC hg19) with hisat2 software. Then, guided by the Ensembl gene-annotation file, cuffdiff software (part of cufflinks) was used to reveal the expression profile of the lncRNAs and mRNAs in terms of Fragments Per Kilobase of transcript per Million mapped reads (FPKM) values, from which the fold change between groups and the corresponding *p*-values were calculated. Subsequently, differentially expressed lncRNAs and mRNAs were identified and lncRNA target genes were predicted by their locations to nearby genes.

Series Test of Clusters (STC)
-----------------------------

STC analysis was used to screen the significant trending models associated with glioma and their corresponding differentially expressed mRNAs and lncRNAs. Fisher\'s exact test was used to identify significant profiles, and *p* ≤ 0.05 was used as a threshold of significance.

Gene Co-expression Analyses
---------------------------

To explore the interactions between the DEGs and differentially expressed lncRNAs, gene co-expression networks were build based on their co-expression patterns. The lncRNAs with a related coefficient of *R* ≥ 0.95 or *R* ≤ −0.95 were screened for functional analysis.

Gene Ontology (GO) Analysis
---------------------------

All differentially expressed genes (DEGs) were mapped to GO terms in the GO database (<http://www.geneontology.org/>). A hypergeometric test was applied to find significantly enriched GO terms in the input list of DEGs, based on "GO::TermFinder" (<http://smd.stanford.edu/help/GO-TermFinder/GO_TermFinder_help.shtml>).

A Bonferroni correction was applied to adjust the *p*-value. The false discovery rate (FDR)-adjusted *p* ≤ 0.05 was used as a threshold and GO terms fulfilling this condition were defined as significantly enriched.

Pathway Analysis
----------------

Pathway analysis was used to identify pathways involving the DEGs, according to the Kyoto Encyclopedia of Genes and Genomics (KEGG). Pathways with FDR-adjusted *p* ≤ 0.05 were defined as significantly enriched. Cytoscape was used to generate graphical representations of the pathways.

Quantitative Real-Time Polymerase Chain Reaction (qRT-PCR)
----------------------------------------------------------

Reverse transcription was performed with the High-Capacity cDNA Reverse Transcription Kits (Applied Biosystems, Foster City, USA), according to the manufacturer\'s instructions. qRT-PCR was performed on an ABI 7500 thermocycler (Applied Biosystems, Foster City, CA, USA) by using SYBR Green Real-Time PCR Master Mix (Toyobo, Japan). GAPDH was used for normalization. All qPCR reactions were performed in biological triplicates. Primer sequences are listed in Supplemental [Table 1](#T1){ref-type="table"}.

###### 

The 50 most significantly differentially expressed lncRNAs.

  **Transcript_ID**   **Gene_ID**                          **Log~**2**~ (fold change)**   ***p*-value**   **Regulation**
  ------------------- ------------------------------------ ------------------------------ --------------- ----------------
  TCONS_l2_00004574   [XLOC_l2_002352](XLOC_l2_002352)     25.4352                        0.00645         Up
  uc031tga.1          [BC018860](BC018860)                 9.58718                        0.01625         Up
  ENST00000412788     [ENSG00000130600](ENSG00000130600)   6.97233                        0.02285         Up
  ENST00000608521     [ENSG00000227195](ENSG00000227195)   6.40785                        0.02125         Up
  uc022adp.1          [GU228584](GU228584)                 5.95802                        0.0006          Up
  ENST00000601079     [ENSG00000227195](ENSG00000227195)   5.85652                        0.0208          Up
  ENST00000549278     [ENSG00000257156](ENSG00000257156)   −5.71737                       0.0278          Down
  ENST00000510667     [ENSG00000249307](ENSG00000249307)   5.59395                        0.028           Up
  ENST00000518934     [ENSG00000254139](ENSG00000254139)   5.3137                         0.00855         Up
  ENST00000451368     [ENSG00000225792](ENSG00000225792)   5.30241                        0.0039          Up
  ENST00000597267     [ENSG00000227195](ENSG00000227195)   5.21331                        0.01125         Up
  uc011ktp.2          [FAM115C](FAM115C)                   5.00654                        0.0466          Up
  ENST00000511634     [ENSG00000248184](ENSG00000248184)   5.00535                        0.03295         Up
  ENST00000509088     [ENSG00000249307](ENSG00000249307)   4.92487                        0.0293          Up
  NR_024443           [LOC100133920](LOC100133920)         4.89535                        0.0483          Up
  ENST00000413670     [ENSG00000225206](ENSG00000225206)   −4.88674                       0.02905         Down
  ENST00000438049     [ENSG00000231419](ENSG00000231419)   4.81286                        0.00125         Up
  ENST00000608254     [ENSG00000233067](ENSG00000233067)   4.81252                        0.0275          Up
  ENST00000537762     [ENSG00000256542](ENSG00000256542)   −4.74613                       0.01925         Down
  NR_034142           [LHFPL3-AS1](LHFPL3-AS1)             4.56925                        0.01805         Up
  ENST00000363359     [ENSG00000265185](ENSG00000265185)   4.46038                        0.0187          Up
  ENST00000413238     [ENSG00000231419](ENSG00000231419)   4.43472                        0.0242          Up
  TCONS_00029193      [XLOC_013852](XLOC_013852)           4.36865                        0.00005         Up
  uc021uec.1          [EPR-1](EPR-1)                       4.26132                        0.03495         Up
  ENST00000447563     [ENSG00000231419](ENSG00000231419)   4.25414                        0.00375         Up
  ENST00000593438     [ENSG00000253552](ENSG00000253552)   4.23103                        0.0426          Up
  ENST00000590421     [ENSG00000267280](ENSG00000267280)   4.21325                        0.0351          Up
  ENST00000555772     [ENSG00000258754](ENSG00000258754)   4.18705                        0.02865         Up
  ENST00000427722     [ENSG00000235326](ENSG00000235326)   4.13483                        0.0311          Up
  ENST00000423456     [ENSG00000214548](ENSG00000214548)   −4.13843                       0.0123          Down
  ENST00000518865     [ENSG00000248690](ENSG00000248690)   4.11723                        0.0477          Up
  ENST00000422842     [ENSG00000234173](ENSG00000234173)   4.10453                        0.002           Up
  ENST00000442411     [ENSG00000224057](ENSG00000224057)   4.07224                        0.0022          Up
  ENST00000581282     [ENSG00000266045](ENSG00000266045)   −4.0662                        0.0117          Down
  uc003tqn.3          [EGFR](EGFR)                         4.05537                        0.00225         Up
  ENST00000262952     [ENSG00000034063](ENSG00000034063)   4.04982                        0.03855         Up
  ENST00000432171     [ENSG00000226786](ENSG00000226786)   4.0389                         0.03535         Up
  ENST00000438810     [ENSG00000224271](ENSG00000224271)   −4.03373                       0.04935         Down
  ENST00000603284     [ENSG00000270866](ENSG00000270866)   4.02231                        0.01445         Up
  ENST00000522718     [ENSG00000253161](ENSG00000253161)   −3.94716                       0.028           Down
  TCONS_00006930      [XLOC_002759](XLOC_002759)           3.93013                        0.04995         Up
  ENST00000425277     [ENSG00000228133](ENSG00000228133)   −3.91056                       0.00215         Down
  uc001zdv.3          [DQ786262](DQ786262)                 3.8969                         0.0171          Up
  ENST00000520255     [ENSG00000254235](ENSG00000254235)   3.89324                        0.03705         Up
  TCONS_00005474      [XLOC_003316](XLOC_003316)           3.86985                        0.01935         Up
  ENST00000563044     [ENSG00000260978](ENSG00000260978)   3.85627                        0.02885         Up
  NR_015364           [LOC441204](LOC441204)               3.85363                        0.0083          Up
  ENST00000423403     [ENSG00000231252](ENSG00000231252)   3.75703                        0.01055         Up
  ENST00000534856     [ENSG00000255931](ENSG00000255931)   −3.73183                       0.0193          Down
  ENST00000499452     [ENSG00000245954](ENSG00000245954)   −3.71881                       0.0161          Down

*Transcript_ID, the transcript ID; Gene_ID, the Ensembl gene identifier; Log~2~ (fold change), fold change between the two groups; p_value, p-value between the two groups; regulation, "up" indicates upregulation, and "down" indicates downregulation*.

Statistical Analysis
--------------------

Student\'s *t*-tests and one-way analyses of variance (ANOVA) with Bonferroni corrections for multiple comparisons were performed to determine significant differences between different groups. A false discovery rate (FDR)-adjusted *p* ≤ 0.05 was regarded as statistically significant. All statistical details are specified in the figure legends.

Results {#s3}
=======

Differentially Expressed lncRNAs and mRNAs in Glioma Tissues Compared With Normal Tissues
-----------------------------------------------------------------------------------------

The lncRNA and mRNA expression levels were compared in glioma tissues and normal tissues. We found 578 lncRNAs and 3,216 mRNAs that were significantly dysregulated in glioma tissues. Among these, 509 lncRNAs and 2,282 mRNAs were upregulated and 69 lncRNAs and 934 mRNAs were downregulated (fold change ≥ 2.0, *p* \< 0.05). We then used hierarchical-clustering analysis to reveal between-group comparisons of lncRNA and mRNA expression levels ([Figures 1A,B](#F1){ref-type="fig"}). In addition, the variation of differential lncRNAs and mRNAs between the glioma and normal groups is shown in a scatter plot ([Figures 1C,D](#F1){ref-type="fig"}). The 30 most significantly differentially expressed lncRNAs and mRNAs are listed in [Tables 1](#T1){ref-type="table"}, [2](#T2){ref-type="table"}. The 20 most significantly differentially expressed lncRNAs and mRNAs in Grade II, III, and IV are listed in [Tables 3](#T3){ref-type="table"}, [4](#T4){ref-type="table"}.

![Differentially expressed lncRNAs and mRNAs in glioma tissues and normal tissues. The hierarchical clustering and heat map show differential lncRNA **(A)** and mRNA **(B)** expression profiles of all targets among samples: red represents high relative expression, and green represents low relative expression. The variation of differential lncRNAs and mRNAs between the glioma and normal groups is shown in a scatter plot **(C,D)**. The red dots and green dots denote a fold change \>2.](fonc-10-00253-g0001){#F1}

###### 

The 50 most significantly differentially expressed mRNAs.

  **Gene**     **Gene_ID**                          **Log~**2**~ (fold change)**   ***p*-value**   **Regulation**
  ------------ ------------------------------------ ------------------------------ --------------- ----------------
  NPTX2        [ENSG00000106236](ENSG00000106236)   −6.07976                       0.00005         Down
  HIST2H3C     [ENSG00000203811](ENSG00000203811)   5.63959                        0.012           Up
  LAMB3        [ENSG00000196878](ENSG00000196878)   −5.55463                       0.00005         Down
  MMP10        [ENSG00000166670](ENSG00000166670)   −5.42366                       0.00355         Down
  HIST1H1B     [ENSG00000184357](ENSG00000184357)   5.25975                        0.0024          Up
  GSTM1        [ENSG00000134184](ENSG00000134184)   5.19776                        0.00005         Up
  ADAMDEC1     [ENSG00000134028](ENSG00000134028)   5.12898                        0.00005         Up
  TOP2A        [ENSG00000131747](ENSG00000131747)   5.10747                        0.00005         Up
  KLRC2        [ENSG00000205809](ENSG00000205809)   5.10461                        0.00065         Up
  BCAN         [ENSG00000132692](ENSG00000132692)   5.07955                        0.00005         Up
  DLL3         [ENSG00000090932](ENSG00000090932)   5.00055                        0.00005         Up
  EGFR         [ENSG00000146648](ENSG00000146648)   4.99159                        0.00005         Up
  HS3ST2       [ENSG00000122254](ENSG00000122254)   −4.95242                       0.0121          Down
  HIST1H3B     [ENSG00000124693](ENSG00000124693)   4.91151                        0.0029          Up
  ACRC         [ENSG00000147174](ENSG00000147174)   −4.87204                       0.00005         Down
  BTBD17       [ENSG00000204347](ENSG00000204347)   4.80482                        0.00435         Up
  HIST1H2BO    [ENSG00000196331](ENSG00000196331)   4.7694                         0.00105         Up
  KLRC4        [ENSG00000183542](ENSG00000183542)   4.62022                        0.0231          Up
  AL450307.1   [ENSG00000189275](ENSG00000189275)   −4.61135                       0.007           Down
  IRX2         [ENSG00000170561](ENSG00000170561)   4.54101                        0.00015         Up
  NEU4         [ENSG00000204099](ENSG00000204099)   4.53795                        0.00005         Up
  F5           [ENSG00000198734](ENSG00000198734)   4.53494                        0.00005         Up
  NTS          [ENSG00000133636](ENSG00000133636)   4.52864                        0.0084          Up
  NEK2         [ENSG00000117650](ENSG00000117650)   4.47922                        0.0003          Up
  TNFRSF6B     [ENSG00000243509](ENSG00000243509)   −4.47257                       0.0445          Down
  CENPA        [ENSG00000115163](ENSG00000115163)   4.46647                        0.00015         Up
  CHST9        [ENSG00000154080](ENSG00000154080)   4.31116                        0.0002          Up
  COL20A1      [ENSG00000101203](ENSG00000101203)   4.29479                        0.00005         Up
  NKAIN4       [ENSG00000101198](ENSG00000101198)   4.22354                        0.00005         Up
  RPE65        [ENSG00000116745](ENSG00000116745)   4.22305                        0.00345         Up
  HIST1H3C     [ENSG00000196532](ENSG00000196532)   4.21731                        0.0029          Up
  SLC38A4      [ENSG00000139209](ENSG00000139209)   4.20996                        0.00105         Up
  PBK          [ENSG00000168078](ENSG00000168078)   4.18686                        0.0012          Up
  NDC80        [ENSG00000080986](ENSG00000080986)   4.17834                        0.0016          Up
  AQP1         [ENSG00000240583](ENSG00000240583)   4.17639                        0.00025         Up
  PDYN         [ENSG00000101327](ENSG00000101327)   −4.16504                       0.00165         Down
  PCDH15       [ENSG00000150275](ENSG00000150275)   4.15302                        0.00005         Up
  POSTN        [ENSG00000133110](ENSG00000133110)   4.12155                        0.00005         Up
  FAM27E1      [ENSG00000237198](ENSG00000237198)   4.11957                        0.03865         Up
  OR2B2        [ENSG00000168131](ENSG00000168131)   4.0847                         0.00965         Up
  HIST1H2AM    [ENSG00000233224](ENSG00000233224)   4.05657                        0.00415         Up
  GNAT1        [ENSG00000114349](ENSG00000114349)   4.04505                        0.00065         Up
  SMOC1        [ENSG00000198732](ENSG00000198732)   4.03992                        0.00005         Up
  ADCYAP1      [ENSG00000141433](ENSG00000141433)   −4.03415                       0.00005         Down
  HAPLN1       [ENSG00000145681](ENSG00000145681)   4.01781                        0.00005         Up
  HIST2H4A     [ENSG00000183941](ENSG00000183941)   4.00519                        0.0003          Up
  IGFBP2       [ENSG00000115457](ENSG00000115457)   3.99938                        0.00015         Up
  MYBL2        [ENSG00000101057](ENSG00000101057)   3.99309                        0.00795         Up
  CDCA2        [ENSG00000184661](ENSG00000184661)   3.97406                        0.0001          Up
  PRLHR        [ENSG00000119973](ENSG00000119973)   3.97111                        0.00155         Up

*Gene, the gene symbol; Gene_ID, the Ensembl gene identifier; Log~2~ (fold change), fold change between the two groups; p_value, p-value between the two groups; regulation, "up" indicates upregulation, and "down" indicates downregulation*.

###### 

The 20 most significantly differentially expressed lncRNAs in Grade II, III, and IV.

  **Grade II**        **Grade III**   **Grade IV**                                       
  ------------------- --------------- ------------------- ---------- ------------------- ----------
  TCONS_l2_00004574   24.3613         TCONS_l2_00004574   25.2656    TCONS_l2_00004575   −173.563
  ENST00000507761     15.4384         NR_028272           −21.3918   TCONS_l2_00004574   26.1453
  ENST00000439232     9.16074         uc031tga.1          10.8534    ENST00000414790     16.2916
  ENST00000429008     7.36223         ENST00000601079     7.41343    ENST00000452769     −14.1961
  ENST00000518934     6.71654         ENST00000597267     6.75795    ENST00000439232     8.48864
  ENST00000509088     6.29573         uc022adp.1          6.31318    TCONS_l2_00004577   −8.28525
  ENST00000511634     6.00731         ENST00000426965     6.26577    ENST00000534856     −6.48133
  ENST00000451368     5.60166         TCONS_00023458      6.15915    ENST00000427775     −6.12229
  ENST00000507491     5.48005         ENST00000453569     6.00558    TCONS_00024611      −5.7225
  ENST00000549278     −5.42917        TCONS_00029193      5.89461    ENST00000525363     5.59857
  NR_120607           −5.25235        ENST00000496499     5.87566    ENST00000554205     −5.52642
  ENST00000413670     −5.08876        ENST00000451368     5.87474    ENST00000568267     −5.4216
  ENST00000534856     −4.95754        ENST00000450618     5.84935    ENST00000511849     −5.35894
  ENST00000519821     4.93422         ENST00000496478     5.83764    ENST00000581282     −5.22225
  ENST00000534584     −4.91577        ENST00000413238     5.6796     ENST00000555928     −5.21035
  ENST00000426585     4.90462         ENST00000475999     5.59518    ENST00000499452     −5.17663
  ENST00000535911     4.84049         ENST00000547748     5.59129    ENST00000509844     −5.16697
  ENST00000499452     −4.82772        TCONS_00029735      5.51277    ENST00000262952     5.08551
  NR_105016           4.52243         ENST00000579362     5.4347     uc021yib.1          −5.07134
  ENST00000432171     4.48445         ENST00000447563     5.432      TCONS_00024610      −5.07118

*Transcript_ID, the transcript ID; Log~2~ (fold change), fold change between the two groups*.

###### 

The 20 most significantly differentially expressed mRNAs in Grade II, III, and IV.

  **Grade II**   **Grade III**   **Grade IV**                           
  -------------- --------------- -------------- ---------- ------------ ----------
  AC003006.7     33.3807         C8B            8.21525    AC003006.7   34.1215
  NKG2-E         14.6013         ADAMDEC1       6.14045    CARTPT       −6.44813
  MMP3           −8.53564        LAMB3          −6.08015   PVALB        −6.30211
  TNFRSF6B       −8.17738        GSTM1          5.80422    AL450307.1   −6.28653
  NPTX2          −6.92934        NPTX2          −5.76227   SERTM1       −6.25538
  KLRC2          6.28025         MMP10          −5.75584   HIST1H1B     6.21729
  SFN            −6.19581        DLL3           5.6937     FAM153C      −6.04122
  CHI3L1         −6.00804        NEU4           5.6856     NPAS4        −6.0054
  F5             5.96362         BCAN           5.62658    HIST2H3C     5.99044
  MMP10          −5.92447        GNAT1          5.51854    TOP2A        5.96605
  TIMP1          −5.72832        COL20A1        5.44559    FAM153A      −5.8515
  LAMB3          −5.66232        HOXA10         5.30305    HIST1H3B     5.82345
  KLRC4          5.57167         DAPL1          5.29865    NPTX2        −5.81806
  PRLHR          5.41416         ACRC           −5.23327   EGFR         5.81172
  ADCYAP1        −5.36875        CDK6           5.23096    HIST1H2BO    5.70465
  AL450307.1     −5.36673        AC005544.1     5.1904     HIST1H4L     5.64717
  PTGS2          −5.30548        OOSP2          5.15603    POSTN        5.63341
  NPAS4          −5.25036        EGFR           5.12739    TCERG1L      −5.60801
  IRX2           5.19441         CTD-2021H9.3   5.09933    WIF1         −5.44568
  SERTM1         −5.15551        C19orf80       5.08284    NRGN         −5.41262

*Gene, the gene symbol; Log~2~ (fold change), fold change between the two groups*.

Model Profile Analysis of lncRNAs and mRNAs in Glioma Tissues and Normal Tissues
--------------------------------------------------------------------------------

To narrow down the number of highly significant differentially expressed lncRNAs and mRNAs, we further analyzed their specific expression patterns. Twenty model profiles of lncRNAs and 10 model profiles of mRNAs were summarized. Among the 20 patterns, we identified nine patterns of lncRNAs that exhibited significant *p*-values ([Figure 2A](#F2){ref-type="fig"}; *p*-values in red boxes).

![Model-profile analysis for differentially expressed lncRNAs associated with the malignancy-grades of gliomas. **(A)** The expression patterns of differentially expressed lncRNAs were analyzed and 20 model profiles were summarized. Each model-expression profile is represented by a box. In total, nine expression patterns of lncRNAs exhibited significant *p*-values (*p* \< 0.05) and the red boxes denote the changing trend of these significant profiles. **(B--D)** The patterns of profiles that have clinical significance are presented.](fonc-10-00253-g0002){#F2}

Among the nine significant patterns, the expression of lncRNAs in profile No. 1, 2, and 22 were of clinical significance ([Figures 2B--D](#F2){ref-type="fig"}). The lncRNA model profile No.1 and No. 2 contained 78 lncRNAs and 58 lncRNAs, respectively, the expressions of which were decreased consistently in glioma tissues (grades II--IV). Additionally, lncRNA profile No. 22 was constructed with 457 lncRNAs, which exhibited consistently up-regulated expression in glioma tissues (grades II--IV).

Establishment of the Gene Co-expression Network for lncRNAs and mRNAs in Glioma Tissues
---------------------------------------------------------------------------------------

To clarify the relationship between lncRNAs and mRNAs in glioma, we performed correlation analyses for lncRNAs and mRNAs in terms of their expression values in glioma tissues. Additionally, a gene co-expression network between mRNAs and lncRNAs was constructed ([Figures 3](#F3){ref-type="fig"}--[5](#F5){ref-type="fig"}). In profile No. 22, there were 83 square nodes and 287 circular nodes that represented lncRNAs and mRNAs, respectively. Moreover, the edges showed the interaction between the lncRNAs and mRNAs. These results indicated that lncRNAs may play vital roles in the pathogenesis of glioma.

![Establishment of the gene co-expression network for lncRNAs in profile No. 1 and the corresponding mRNAs. Here, 33 square nodes and 244 circular nodes represent lncRNAs and mRNAs, respectively. The edges show the interaction between the lncRNAs and mRNAs.](fonc-10-00253-g0003){#F3}

![Establishment of the gene co-expression network for lncRNAs in profile No. 2 and the corresponding mRNAs. Here, 24 square nodes and 258 circular nodes represent lncRNAs and mRNAs, respectively. The edges show the interaction between the lncRNAs and mRNAs.](fonc-10-00253-g0004){#F4}

![Establishment of the gene co-expression network for lncRNAs in profile No. 22 and the corresponding mRNAs. Here, 83 square nodes and 287 circular nodes represent lncRNAs and mRNAs, respectively. The edges show the interaction between the lncRNAs and mRNAs.](fonc-10-00253-g0005){#F5}

GO- and Pathway-Enrichment Analyses of Differentially Expressed lncRNAs
-----------------------------------------------------------------------

To further identify the functional roles of these differential lncRNAs found to be dysregulated in the tumor group, we conducted GO-enrichment and pathway-enrichment analyses. The GO analysis returned terms associated with three categories: molecular function (MF), cellular component (CC), and biological process (BP). The number of lncRNAs in profile No. 22 found associated with each GO term was counted and are shown in a pie chart ([Figure 6](#F6){ref-type="fig"}). The 10 most enriched GO terms (in descending order of enrichment score) within the three categories are shown in [Figures 6D--F](#F6){ref-type="fig"}.

![GO-enrichment analysis of differentially expressed lncRNAs. Each category (BP, CC, and MF) has its classifications and the lncRNAs associated with each category were counted and visualized as pie charts **(A--C)**. The 10 most enriched GO terms (in descending order of enrichment score) in the three categories are shown **(D--F)**.](fonc-10-00253-g0006){#F6}

Furthermore, KEGG pathway analysis demonstrated that the differentially expressed lncRNAs were significantly enriched in various important pathways. The dot plot in [Figure 7A](#F7){ref-type="fig"} shows the eight highest enrichment scores (lowest log~10~ *p*-values) of the significant pathways ([Figure 7A](#F7){ref-type="fig"}), and [Figure 7B](#F7){ref-type="fig"} shows the regulatory roles of the lncRNAs involved in cancer pathways.

![Pathway-enrichment analysis of differentially expressed lncRNAs. The dot plot shows the top-eight enrichment scores (--log~10~ *p*-value) of the significantly enriched pathways **(A)** and the regulatory roles of the lncRNAs involved in the pathways in cancer. **(B)** Nodes in orange are associated with up-regulated enriched genes, whereas green nodes denote genes that showed no statistical significance.](fonc-10-00253-g0007){#F7}

GO- and Pathway-Enrichment Analyses of Differentially Expressed mRNAs
---------------------------------------------------------------------

Since the functions of the differentially expressed mRNAs are different from those of the lncRNAs, we conducted independent GO-enrichment and pathway-enrichment analyses for the mRNAs. [Figure 8](#F8){ref-type="fig"} shows the number of mRNAs associated with each GO term ([Figures 8A--C](#F8){ref-type="fig"}), and the 10 most enriched GO terms (in descending order of enrichment score) in each of the three categories are shown in [Figures 8D--F](#F8){ref-type="fig"}.

![GO-enrichment analysis of differentially expressed mRNAs. Each GO category has many different related terms and the mRNAs associated with each term were counted and visualized as pie charts. **(A--C)** The 10 most enriched GO terms (in descending order of enrichment score) of the three categories are shown **(D--F)**.](fonc-10-00253-g0008){#F8}

As observed with the lncRNAs, KEGG pathway analysis demonstrated that the differentially expressed mRNAs were significantly enriched in various important pathways. The dot plot shows the eight most significantly enriched pathways (enrichment score = --log~10~ *p*-value) ([Figure 9A](#F9){ref-type="fig"}), and the regulatory roles of the mRNAs involved in systemic lupus erythematosus and the staphylococcus aureus infections are shown in [Figure 9B](#F9){ref-type="fig"}.

![Pathway-enrichment analysis of differentially expressed mRNAs. The dot plot shows the top-ten enrichment scores (--log~10~ *p*-values) of the significantly enriched pathways **(A)** and the regulatory roles of the mRNAs involved in systemic lupus erythematosus. **(B)** Orange nodes are associated with up-regulated enriched genes, whereas green nodes denote genes that showed no statistical significance.](fonc-10-00253-g0009){#F9}

Validation of Sequencing Results by qRT-PCR
-------------------------------------------

To validate the sequencing data and bioinformatic results, the five most differentially expressed lncRNAs (TCONS_l2_00004574, uc031tga.1, ENST00000412788, ENST00000608521, and uc022adp.1) and mRNAs (NPTX2, HIST2H3C, LAMB3, MMP10, and HIST1H1B) were selected for qRT-PCR. In agreement with our sequencing results, three of the five lncRNAs (TCONS_l2_00004574, uc031tga.1, and uc022adp.1) and four of the five mRNAs (NPTX2, HIST2H3C, MMP10, and HIST1H1B) were found to be differentially expressed in the glioma samples (*P* \< 0.05; [Figure 10](#F10){ref-type="fig"}).

![Validation of sequencing results by qRT-PCR. Three of the five lncRNAs (TCONS_l2_00004574, uc031tga.1, and uc022adp.1) **(A)** and four of the five mRNAs (NPTX2, HIST2H3C, MMP10, and HIST1H1B) **(B)** were found to be differentially expressed in the glioma samples, which were in agreement with our sequencing results. ^\*^*P* \< 0.05, ^\*\*^*P* \< 0.01, ^\*\*\*^*P* \< 0.001.](fonc-10-00253-g0010){#F10}

Discussion {#s4}
==========

As new research techniques have developed, a growing number of high-throughput platforms have been used to analyze gene expression in glioma. However, previous studies mostly focused on mRNA, DNA, or protein levels in glioblastoma or high-grade glioma using proteomics or microarrays ([@B24]--[@B26]). In the present study, we assessed the significantly differentially expressed lncRNAs and mRNAs between normal tissues and glioma tissues using high-throughput sequencing. To our knowledge, this study is the first to identify the pathological grade-associated transcriptome profiles of lncRNAs and mRNAs in glioma. We identified 578 lncRNAs and 3,216 mRNAs that were significantly dysregulated in glioma tissues. Among these, 509 lncRNAs and 2,282 mRNAs were upregulated, whereas 69 lncRNAs and 934 mRNAs were downregulated (fold change ≥ 2, *p* \< 0.05). This result indicated that these lncRNAs and mRNAs may be involved in glioma initiation and/or progression. However, further research is required to elucidate the detailed mechanisms of the involvement of these lncRNAs and mRNAs in glioma.

The lncRNAs and mRNAs that dynamically changed with differing degrees of glioma malignancy may play crucial biological roles in the disease process ([@B27], [@B28]). Through model-profile analysis, the dynamic expression profiles of lncRNAs and mRNAs were obtained, and the nine significant dynamic expression profiles of lncRNAs were then screened. The three profiles of clinical significance were profiles No. 1, No. 2, and No. 22. Each of these profiles contained a large number of lncRNAs that were consistently down- or up-regulated in the different grades of glioma tissues. In the most significant profile (No. 22), seven lncRNAs were identified to be involved in viral carcinogenesis. The lncRNAs with significant dynamic-expression changes may be more correlated with the malignancy of glioma and, hence, may play vital roles in the regulation of glioma initiation and progression.

To further discern the key lncRNAs associated with glioma, we integrated lncRNA and mRNA co-expression networks in profiles No. 1, No. 2, and No. 22. In total, 83 lncRNAs and 287 mRNAs were identified to play vital regulatory roles in model profile No. 22. Many studies have reported that a large number of lncRNAs, such as ZEB1-AS1 and PCNA-AS1 ([@B29], [@B30]) played important roles in the accurate and complicated co-expression networks. We screened a number of lncRNAs and mRNAs that included key genes that are closely associated with the pathogenesis of glioma. For example, SOX21 has been reported to be closely related to the tumorigenesis of glioblastoma, hepatocellular carcinoma, and colorectal cancer ([@B31]--[@B33]). This suggests that these co-expressed lncRNAs and mRNAs may participate in cancer-related pathways. It was also found that most lncRNAs can be co-expressed with various mRNAs, indicating that each lncRNA may regulate many mRNAs.

A growing number of lncRNAs have been identified in tumors ([@B34], [@B35]); however, the various functions of lncRNAs still remain poorly characterized. To infer the functional roles of the lncRNAs in glioma, GO and pathway analyses were performed for these differentially expressed lncRNAs. The GO analysis indicated that these lncRNAs are most significantly enriched in domains of "biological regulation," "metabolic process," and "regulation of biological process," which are strongly associated with glioma. In addition, the pathway analysis revealed that "pathway in cancer," "calcium signaling pathway," "cAMP signaling pathway," and "Ras signaling pathway" are related with the pathogenic process of glioma.

In addition, there were also some limitations of our present study. Regardless of the technology performed to detect expression levels and the sample sizes that are used, the actual gene expression levels vary among individuals because expression is a random process. Consequently, the analysis data may not be powerful enough to reflect these actual expression levels across individuals. However, biological variability will decrease with the increase of the scale of samples. Therefore, we will perform further studies with more samples in the future.

Conclusions {#s5}
===========

In summary, we characterized the expression profiles of lncRNAs and mRNAs in normal tissues and glioma tissues (WHO grades II--IV). Then, we analyzed the dynamic differentially expressed profiles of lncRNAs and mRNAs, which indicated their potential vital roles in gliomas with different degrees of malignancy. A series of bioinformatics analyses indicated that most of these lncRNAs and mRNAs are involved in important biological processes and pathways associated with the pathogenesis of glioma. These results provide potential directions and valuable resources for future studies via the comprehensive integration of these lncRNAs and mRNAs.
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